Exact Sciences Completes 54,000 Cologuard Tests During the Second Quarter


Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially
Cash utilization and gross margin improve

MADISON, Wis., July 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $21.2 million during the second quarter ended June 30, 2016, representing a 161-percent increase from $8.1 million in the second quarter of 2015. The company completed approximately 54,000 Cologuard tests during the second quarter, an increase of approximately 160 percent compared to the 21,000 tests completed during the same period of 2015. Since Cologuard's launch and through the end of the second quarter of 2016, approximately 41,000 physicians have ordered the test.

Read More

NCQA Proposes Inclusion of Cologuard in 2017 HEDIS Quality Measures

Updated HEDIS Measures Would Align with Final USPSTF Recommendations

MADISON, Wis., July 13, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced that the National Committee for Quality Assurance (NCQA) has proposed to broaden the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening to include Cologuard® on a three-year schedule.

"Inclusion in the HEDIS quality measures is an important milestone toward Cologuard becoming a standard of care for colon cancer screening," said Kevin Conroy, chairman and CEO of Exact Sciences.  "Physicians, health systems and insurers would receive quality credit for using this patient-friendly screening option, which we believe will hasten its adoption."

Read More

Topics: Exact Sciences News